Dr Gary Pace, BSc (Hons I), MSc, PhD
Chairman & Partner
Dr. Gary Pace is an experienced serial entrepreneur, director and senior operations manager of small to large-scale life sciences ventures in Australia, New Zealand and the USA. He has more than 40 years of experience in the development and commercialization of advanced technologies including in the biotechnology, pharmaceuticals, medical devices and food industries.
Dr Pace currently serves as a Director of Pacira Pharmaceuticals Inc (NASDAQ: PCRX), Cardiff Oncology (NASDAQ: CRDF), Simavita Ltd (ASX: SVA) and Antisense Therapeutics (ASX: ANP) and several private companies.
He also served as a director of ResMed Inc (NYSE: RMD) from its inception in 1994 until 2018. Gary was instrumental in the growth of the company to a market capitalization of US$28bn.
In New Zealand, he is Executive Chairman of InsituGen, which is developing tests to detect performance enhancing drugs in racehorses and humans. Also, he is a director of Upstream Medical Technologies, which is developing biomarker-based tests for rapid and accurate front-line diagnoses of heart disease and associated clinical complications.
He has also previously served as a director of two Pacific Channel portfolio companies that have since been acquired; Somnaceutics and Engender Technologies.
Dr. Pace holds a B.Sc. (Hons I) from the University of New South Wales and a Ph.D. from the Massachusetts Institute of Technology where he was a Fulbright Fellow and General Foods Scholar. He has authored or co-authored over 50 research and review papers plus 24 patents. He has held visiting academic positions at the Massachusetts Institute of Technology and the University of Queensland. Dr. Pace is an elected Fellow of the Australian Academy of Technological Sciences and Engineering. In 2003 he was awarded a Centenary Medal by the Australian Government “for service to Australian society in research and development” and in was named 2011 Director of the Year (corporate governance) by the San Diego Directors Forum.
Dr. Pace was born in Sydney Australia and holds both US and Australian citizenship. He lives in La Jolla, California, USA.
Brent Ogilvie, BSc. (Bio.), MBA, CFIP (INFINZ (Cert)), Member of the Institute of Directors
Brent Ogilvie is co-founder and Managing Director of Pacific Channel. Through Pacific Channel activities as a seed investor, Mr. Ogilvie serves as Director of:
- Breathe Easy Limited
- Living Green Group Limited
- Vortex Power Systems Limited
- Diasense Limited
Mr Ogilvie was also previously Director of:
- Engender Technologies Limited, which developed a proprietary process to separate X (female) and Y (male) bearing bull sperm cells to enable cattle farmers to choose the sex of offspring. Mr Ogilvie co-founded Engender and led it from foundation to its successful sale to a global dairy genetics company generating a significant capital return for its scientists, Auckland UniServices and Pacific Channel’s co-investors.
- Somnaceutics Limited, which successfully developed and sold the intellectual property of a sleep-enhancement tonic and its other business assets to an NZX-listed company;
- Ecodiesel Limited, a biodiesel technology company that sold its business assets to Z Energy.
He is a Council Member of the Angel Association of New Zealand.
Prior to founding Pacific Channel, Mr Ogilvie was New Zealand Consul & Trade Commissioner to New York. He was formerly an industrial product manager for a global corporation and an advisor to New Zealand start-ups.
Dr Roland Toder B.Sc (Hons), PhD
Dr Roland Toder has extensive life sciences and international business development expertise. He has previously worked as a manager, board member and consultant to numerous successful companies in NZ and in Europe. Roland brings a wealth of knowledge to Pacific Channel and helps the team with technical due diligence, scientific validation, pre-money valuation of early start ups, technology transfer, international licensing as well as advising on the commercial arrangements of our portfolio companies.
Roland resides in Golden Bay, NZ and holds dual Citizenship in Germany & New Zealand.
Lachlan Nixon, LLB, BMus
Lachlan Nixon is an integral part of the team and assists Pacific Channel and its portfolio companies with a wide variety of activities.
His principal focus is on securing further resources (other investors, people, synergistic technologies and commercial partners) into our portfolio companies. He is experienced in conceptualizing and structuring transactions to secure these resources to the benefit of all stakeholders.
He is also involved in evaluating and assessing investment opportunities and has led investments into several deep-tech companies during his time at Pacific Channel. He is particularly adept at the technology transfer process of forming private companies around ground-breaking technologies developed at research institutions and preparing them for investment.
Lachlan also works with several of our companies operationally post-investment to create value. He primarily supports our portfolio companies on business development, commercial strategy, investment readiness, M&A and capital raising.
Lachlan has a genuine passion for helping early stage and high growth New Zealand companies to achieve success and has added great value to our work with entrepreneurs, investors and corporates.
Lachlan is currently a director of Pacific Channel portfolio companies Terax and A1.
Lachlan holds degrees in law and music and is an admitted Barrister and Solicitor of the High Court of New Zealand.
Dr Robert Powell, Ph.D, MBA, M.Inst.Dir
Dr. Robert Powell, Ph.D., MBA, M.Inst.Dir. (Investment Manager), has 15 years’ experience identifying opportunities, forming and nurturing deep-tech ventures.
A former academic, Robert worked on the academic side of the commercialisation process managing the commercialisation program for a US biotechnology focused research University.
For the last decade he has worked for investors (Angel and VC) in the US and NZ, while managing a deep-tech due diligence consultancy. He returned to NZ five years ago after two decades in the US. Robert brings broad experience having worked with medical, human, animal and aquatic technologies and start-ups. He has experience in forming, financing, operating and staffing deep-tech ventures.
Perzaan Mehta, BE(Hons), BCom
Perzaan Mehta joined Pacific Channel late 2016 as an Analyst focused on engineering and cleantech start-ups. He has a keen interest in renewable technologies having conducted research into floating wind turbines at university. Perzaan is responsible for identifying and reviewing technologies for investment and developing commercialisation pathways for our portfolio companies. Prior to joining Pacific Channel, he worked with GEA, a German multinational engineering firm in the supply chain and operations management team of Asia pacific where he led a project in the development of operational processes. Perzaan has completed a BE(Hons) in Mechatronics engineering and a BCom in Finance and Economics from the University of Auckland.
Emerald Scofield joined Pacific Channel as an analyst with a focus on biotech and medical tech start-ups. Emerald is interested in technologies that revolutionise healthcare via improving accessibility and quality of care. Emerald is responsible for technology review for investment and developing commercialisation strategies for portfolio companies. Emerald has recently completed her BSc in Biotechnology at the University of Auckland.
Robert McPhail joined our team as an Investment Analyst in 2019.
Robert’s primary role is to provide support to management with capital raising activities, where Pacific Channel is the lead investor or existing shareholder. He will also assist with corporate strategy and corporate governance to our companies.
Robert is also involved in the due-diligence investment process to assess whether technologies are commercially viable. In addition to this, he assists new ventures with legal structuring and creates legal contracts for our portfolio companies.
Robert has a passion for Biotechnology and Ag-technology start up’s in NZ and joins our team with excitement to drive growth across our portfolio companies. He has recently completed a Batchelor’s of Law and Batchelor of Commerce majoring in Accounting.
Lifei Wang, B.Comm
Lifei Wang joined Pacific Channel in 2017 as part of the Greater China Team. Lifei is involved in marketing and
attracting investment, acquirers and strategic parties from the Greater China region to our portfolio companies. Lifei has connections with Chinese media outlets, which allow for publicity of Pacific Channel and our portfolio.
Lifei has extensive experience in marketing, with a New Zealand Level 7 Diploma in Business & Marketing.
While in working China, Lifei gained extensive experience in journalism and developing marketing campaigns for a large local news outlet in Beijing.
Tina Tian, MD, LLM
Greater China Manager
Tina Tian was appointed as part of our growing focus on Chinese networks and serves as our Greater China Manager. Tina focuses on attracting investment, acquirers and strategic parties from the Greater China region to our portfolio companies.
Tina has Bachelor of Clinical Medicine from a Chinese University and worked as a doctor in a Chinese Hospital for five years. She also has a Master of Laws, with a focus on Chinese Financial Law, and has previously worked as the in-house Legal Counsel for a large Chinese corporate for 11 years.
Blair Pritchard, BA. (Econ), LLB, GAICD
Blair Pritchard was previously a Partner at Pacific Channel but is still involved in an advisory capacity. He is now based in Sydney, where he is a director of the Clean Energy Finance Corporation (CEFC). At the CEFC, he is responsible for increasing the innovative and early stage investing activities. This includes pioneering new investment programs designed to promote clean energy innovation, investing directly in early stage companies, and advising such companies on growth strategies.
Blair was the Chief Investment Officer of My Angel Investment, an equity crowdfunding platform as well as the CFO of Phoenix Water, a Melbourne based water technology company
Blair has also worked at Macquarie, where he ran a team making principal investments in early stage clean-tech and environmental companies as part of the Macquarie Group. This role included setting up/acquiring early stage companies and remaining actively involved in their ongoing management including Board representation. The business reached profitability after two years.
Prior to that he acted as Chief Investment Officer of a $7bn funds management unit within Macquarie. Earlier in his career, Blair worked as an investment analyst for Mercer Investment Consulting, performing asset-liability modelling for Australian pension funds.
Blair’s areas of interest include financial structuring and product development cycles in early stage companies. He has law and economics degrees from Victoria University of Wellington and is a graduate of the Australian Institute of Company Directors.
Kieran Jina, MSc (Hons), MBioEnt (Hons)
Kieran Jina has experience in assessing investment opportunities, assisting and managing early stage life-science and engineering based ventures from conceptualisation, through to becoming investment ready. Mr Jina manages the development and commercialisation programmes of early stage ventures. Since joining Pacific Channel in May 2015, Mr Jina has held a range of operational and analytical roles in Pacific Channel’s portfolio companies to facilitate their growth and investment, including as Operations Manager for Engender Technologies, Pheromite and Orbis Diagnostics.
Mr Jina’s principal interest is in technology commercialisation, especially opportunity analysis and intellectual property strategy. Mr Jina has experience in performing initial due diligence review of life science technologies for investment, including technical review, assessment of technology development plans, analysis of competing technologies and review of market potential.
Prior to joining Pacific Channel, Mr Jina was the Market Analyst at Aroa Biosurgery, a NZ-based reconstructive surgery medical device company, which was named the 12th fastest growing company in NZ by the Deloitte Fast 50.
Mr Jina holds a MSc (Hons) (Biomedical Science), investigating reproductive immunology, and MBioEnt (Hons) (Bioscience Enterprise), investigating value drivers for medical devices, from The University of Auckland.